Cargando…

Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study

BACKGROUND AND AIMS: Individualization of treatment with peginterferon alfa and ribavirin in patients with chronic hepatitis C showed benefit in controlled trials and was implemented in treatment guidelines to increase response rates and to reduce side effects and costs. However, it is unknown wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, Wolf Peter, Mauss, Stefan, Lutz, Thomas, Schober, Andreas, Böker, Klaus, Moog, Gero, Baumgarten, Axel, Pfeiffer-Vornkahl, Heike, Alshuth, Ulrich, Hüppe, Dietrich, Wedemeyer, Heiner, Manns, Michael P., Schott, Eckart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521757/
https://www.ncbi.nlm.nih.gov/pubmed/26230998
http://dx.doi.org/10.1371/journal.pone.0134839
_version_ 1782383852477480960
author Hofmann, Wolf Peter
Mauss, Stefan
Lutz, Thomas
Schober, Andreas
Böker, Klaus
Moog, Gero
Baumgarten, Axel
Pfeiffer-Vornkahl, Heike
Alshuth, Ulrich
Hüppe, Dietrich
Wedemeyer, Heiner
Manns, Michael P.
Schott, Eckart
author_facet Hofmann, Wolf Peter
Mauss, Stefan
Lutz, Thomas
Schober, Andreas
Böker, Klaus
Moog, Gero
Baumgarten, Axel
Pfeiffer-Vornkahl, Heike
Alshuth, Ulrich
Hüppe, Dietrich
Wedemeyer, Heiner
Manns, Michael P.
Schott, Eckart
author_sort Hofmann, Wolf Peter
collection PubMed
description BACKGROUND AND AIMS: Individualization of treatment with peginterferon alfa and ribavirin in patients with chronic hepatitis C showed benefit in controlled trials and was implemented in treatment guidelines to increase response rates and to reduce side effects and costs. However, it is unknown whether individualization was adopted in routine daily practice and whether it translated into improved outcomes. METHODS: From a large noninterventional cohort study, clinical and virologic response data of 10,262 HCV patients who received peginterferon alfa-2a and ribavirin between 2003-2007 and 2008-2011 were analyzed. To account for treatment individualization, a matched-pair analysis (2,997 matched pairs) was performed. Variation in treatment duration and dosing of ribavirin were analyzed as indicators for individualization. RESULTS: Sustained virological response (SVR) rates were similar between 2003-2007 and 2008-2011 (62.0% vs. 63.7%). Patients with comorbidities were more abundant in the later period, (44.3% vs. 57.1%). The subsequent matched-pair analysis demonstrated higher SVR rates in the 2008-2011 period (64.3%) than in the 2003-2007 period (61.2%, p=0.008). More patients received abbreviated or extended treatment regimens in the later than the earlier period as an indicator of treatment individualization. To the same end, ribavirin doses were higher in the later period (12.6 versus 11.6 mg/kg/day). Factors independently associated with SVR included HCV genotype, low baseline viral load, younger age, route of infection, absence of concomitant diseases, lower APRI score, normal gamma-GT, higher ribavirin doses, no substitution for drug abuse, treatment duration, and treatment in the 2008-2011 period. CONCLUSIONS: Treatment individualization with peginterferon alfa and ribavirin was implemented in daily routine between 2003-2007 and 2008-2011, SVR rates improved in the same period. These findings may be most relevant in resource-limited settings.
format Online
Article
Text
id pubmed-4521757
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45217572015-08-06 Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study Hofmann, Wolf Peter Mauss, Stefan Lutz, Thomas Schober, Andreas Böker, Klaus Moog, Gero Baumgarten, Axel Pfeiffer-Vornkahl, Heike Alshuth, Ulrich Hüppe, Dietrich Wedemeyer, Heiner Manns, Michael P. Schott, Eckart PLoS One Research Article BACKGROUND AND AIMS: Individualization of treatment with peginterferon alfa and ribavirin in patients with chronic hepatitis C showed benefit in controlled trials and was implemented in treatment guidelines to increase response rates and to reduce side effects and costs. However, it is unknown whether individualization was adopted in routine daily practice and whether it translated into improved outcomes. METHODS: From a large noninterventional cohort study, clinical and virologic response data of 10,262 HCV patients who received peginterferon alfa-2a and ribavirin between 2003-2007 and 2008-2011 were analyzed. To account for treatment individualization, a matched-pair analysis (2,997 matched pairs) was performed. Variation in treatment duration and dosing of ribavirin were analyzed as indicators for individualization. RESULTS: Sustained virological response (SVR) rates were similar between 2003-2007 and 2008-2011 (62.0% vs. 63.7%). Patients with comorbidities were more abundant in the later period, (44.3% vs. 57.1%). The subsequent matched-pair analysis demonstrated higher SVR rates in the 2008-2011 period (64.3%) than in the 2003-2007 period (61.2%, p=0.008). More patients received abbreviated or extended treatment regimens in the later than the earlier period as an indicator of treatment individualization. To the same end, ribavirin doses were higher in the later period (12.6 versus 11.6 mg/kg/day). Factors independently associated with SVR included HCV genotype, low baseline viral load, younger age, route of infection, absence of concomitant diseases, lower APRI score, normal gamma-GT, higher ribavirin doses, no substitution for drug abuse, treatment duration, and treatment in the 2008-2011 period. CONCLUSIONS: Treatment individualization with peginterferon alfa and ribavirin was implemented in daily routine between 2003-2007 and 2008-2011, SVR rates improved in the same period. These findings may be most relevant in resource-limited settings. Public Library of Science 2015-07-31 /pmc/articles/PMC4521757/ /pubmed/26230998 http://dx.doi.org/10.1371/journal.pone.0134839 Text en © 2015 Hofmann et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Hofmann, Wolf Peter
Mauss, Stefan
Lutz, Thomas
Schober, Andreas
Böker, Klaus
Moog, Gero
Baumgarten, Axel
Pfeiffer-Vornkahl, Heike
Alshuth, Ulrich
Hüppe, Dietrich
Wedemeyer, Heiner
Manns, Michael P.
Schott, Eckart
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
title Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
title_full Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
title_fullStr Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
title_full_unstemmed Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
title_short Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
title_sort benefit of treatment individualization in patients with chronic hepatitis c receiving peginterferon alfa-2a and ribavirin in a large noninterventional cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521757/
https://www.ncbi.nlm.nih.gov/pubmed/26230998
http://dx.doi.org/10.1371/journal.pone.0134839
work_keys_str_mv AT hofmannwolfpeter benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT maussstefan benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT lutzthomas benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT schoberandreas benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT bokerklaus benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT mooggero benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT baumgartenaxel benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT pfeiffervornkahlheike benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT alshuthulrich benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT huppedietrich benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT wedemeyerheiner benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT mannsmichaelp benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy
AT schotteckart benefitoftreatmentindividualizationinpatientswithchronichepatitiscreceivingpeginterferonalfa2aandribavirininalargenoninterventionalcohortstudy